Swiftmerge Acquisition Corp. terminates merger with HDL Therapeutics by mutual agreement

AleAnna, Inc.

Merger agreement dated August 11, 2023 terminated as of February 14, 2024.
No termination fee or other payment due to either party under the Mutual Termination Agreement.
All parties released each other from any and all claims arising under the merger agreement.
Confidentiality obligations between Swiftmerge and HDL Therapeutics survive the termination.
Swiftmerge must now pursue an alternative business combination or face potential liquidation.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

AleAnna, Inc. terminated Merger Agreement and Mutual Termination Agreement with HDL Therapeutics, Inc., and IVCP Merger Sub, Inc. valued at Mutual termination of Merger Agreement; no termination fee. (effective 2024-02-14).

Action: termination
Agreement: merger
Counterparty: HDL Therapeutics, Inc., and IVCP Merger Sub, Inc.
Value: Mutual termination of Merger Agreement; no termination fee.
Effective: 2024-02-14

Exact text from the filing

On February 14, 2024, the Company, HDL and Merger Sub entered into a Mutual Termination Agreement (the “ Mutual Termination Agreement ”) pursuant to which they terminated the Merger Agreement by mutual agreement in accordance with Section 10.1(d) thereof, and each party, on behalf of itself and its agents, released, waived and forever discharged the other parties and their agents of and from any and all obligation or liability arising under the Merger Agreement.

View on SEC.gov

548 material agreements filed in the last 30 days. Browse all material agreements →

AleAnna, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-036776

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.